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WhiletraditionalChinesemedicine (TCM) is widely used amongChinesepatients with cancer, studies evaluating theeﬀectiveness
of TCM using objective indicators are rare. We examined the eﬀectiveness of TCM for liver protection and completion of
chemotherapy amongpatients with cancer receiving chemotherapy. We used a case-controldesign to examine the medical records
ofpatients with cancer whoreceived chemotherapy in a teaching hospitalin Taipei in 2004.A totalof184courses ofchemotherapy
among 89 patients were studied. Of the 184 courses, 42 used TCM jointly with chemotherapy served as cases, while the remaining
142 courses served as controls. Outcome variables included counts of cancelled or delayed chemotherapies and liver function
(aspartate aminotransferase, AST and alanine aminotransferase, ALT) 1 week before, during and 2 weeks after chemotherapy.
Generalized estimating equations were used to analyze the data. Patients who had concomitant TCM with chemotherapy had
lower serum ALT and AST during chemotherapy than the controls given that the age, sex, cancer stage, radiotherapy sites, cancer
diagnosisandpotentialhepatotoxicityofthechemotherapeuticdrugs werecontrolledforinthemodel[β = −3.48,95%conﬁdence
interval (CI) −10.08 to 3.11 for AST; β = −5.95, 95% CI: −11.47 to −0.44 for ALT]. There was no signiﬁcant diﬀerence between
the case and control groups for odds of completing one course of chemotherapy. Use of TCM with chemotherapy resulted in
protection of the liver during chemotherapy, as manifested by lower serum AST and ALT levels.
1.Introduction
Hepatotoxicity is a common side eﬀect of chemotherapy
[1]. Prevalence of hepatotoxicity ranges from 33 to 65.6%
among patients with cancer [2, 3], and up to 30% of
patients have the third or fourth degree hepatotoxicity [4].
Although 90% of patients resumed normal liver function
after stopping use of hepatotoxic drugs [3], elevation of liver
enzymes was sometimes accompanied by severe thrombo-
cytopenia and other aggravated side eﬀects [5, 6]. Current
chemotherapeuticguidelinesrequirestoppingchemotherapy
when hepatotoxicity, as indicated by AST and ALT levels,
reaches four times the upper normal limit (>100Ul−1)[ 7].
Studiesnoted that 56–90.5% of cancer patients had to cancel
or delay chemotherapy due to serious complications [2, 3].
Changes in chemotherapy courses and drug doses reduced
response rates to treatment from 68 to 30% [8].
Use of complementary and alternative medicine (CAM)
among patients with cancer has becomeincreasingly popular
duringthepastfewdecades.Asystematicreviewincluding26
s u r v e y so fc a n c e rp a t i e n t sf r o m1 3c o u n t r i e ss h o w e dt h a tt h e
prevalence of CAM use ranged from 7 to 64% [9]. In 2002,
a survey of patients with breast, colon or prostate cancer
foundthat70.2%ofrespondentsusedCAM[10].Traditional
Chinese medicine (TCM) is popular among people with a
Chinese background.
Taiwan has atwo-tieredmedicalsystem, comprisingboth
modern medicine and TCM. These two systems operate in
parallel and the medical expenses of both are covered by the
National Health Insurance system in Taiwan. Studies showed2 Evidence-Based Complementary and Alternative Medicine
that 9–64% of patients with cancer used TCM in Taiwan
[11–16]. According to recent statistics, 72 Western medical
hospitals in Taiwan set up departments of TCM, which
make it feasible to treat cancer with an integrative system of
modern medicine and TCM [17]. While anecdotal evidence
shows that TCM protects liver function, TCM used varied
across studies and target groups were not conﬁned to cancer
patients.Reportsofactive management ofliverinjury related
to chemotherapy are lacking in the literature [18, 19]. To the
bestofourknowledge,nostudyevaluatedtheeﬀectivenessof
TCM using objective indicators among patients with cancer
receiving chemotherapy. The purpose of this study was 2-
f o l d :t oe x a m i n et h ee ﬀectiveness of TCM for protecting the
liverfromthetoxiceﬀectsofchemotherapy andtodetermine
if chemotherapy completion rates improved among patients
with cancer receiving joint TCM and chemotherapy.
2.Methods
We applied a case-control study design. Two senior oncology
nurses used a structured questionnaire to independently
abstract data from patients’ medical records. Inconsistent
data were compared, and a consensus on questionable data
was reached throughdiscussion among the two dataabstrac-
tors and the oncologists. Inconsistent data were uncommon
and were mostly concerned with determining the timing of
the data.
This study was a chart review study and involved no
contact with the patients. After data abstraction completed,
patient names were replaced by coded numbers to ensure
anonymity. The study was approved by the human subjects
committee at the study hospital (approval number CRC-08-
09-03issuedinMay2009).Writtenconsentwasnotrequired,
since patient identiﬁers were not included in the data.
2.1. Participants. All patients considered for the study had
diagnoses of cancer, were older than 20 years of age, and
were treated for cancer using chemotherapy in a teaching
hospital in Taipei from January 2004 to December 2004.
The study hospital oﬀered both TCM and Western hemo-
oncology services. Patients were referred by their oncologist
or were self referred for TCM services. Thus, there was no
gate-keeping system or formal referral criteria for medical
treatment.
A total of 89 patients with cancer were identiﬁed from
the medical records and their data were analyzed. Of the 89
patients, 37 (42%) ever received TCM prescribed by licensed
TCM doctors, while 52 (58%) received modern medical
treatments only. Among the 89 patients, 184 chemotherapy
courses were identiﬁed. Of the 184 courses, 42 (23%) were
given in conjunction with TCM (case group), and the
remaining 142 (77%) courses without joint TCM served as
the control group. Thus, the unit of analysis was one course
of chemotherapy.
2.2. Treatment Protocols. Patients had blood tests for AST
and ALT before the start of a course of chemotherapy
and once a week thereafter, according to hospital routine.
Patients were advised to fast (nothing by mouth) for eight
hours before the blood tests. The blood-testing instrument
was calibrated daily by qualiﬁed technicians at the study
hospital. The TCM medication used were Xiao-Chai-Hu-
Tang, Huang-Lian-Jie-Du-Tang or Yin-Chen-Wu-Ling-San
during chemotherapy, based on patient conditions as judged
by TCM doctors. These TCM medications were traditional
multi-component medications. According to TCM theory,
these preparations strengthen liver function and detoxify the
liver [20, 21] Botanical names for the components of the
TCMs are presented in Table 1.T C Mm e d i c a t i o n su s e di n
this study were concentrated herbal extracts in the form
of powders produced by a GMP-certiﬁed pharmaceutical
company in Taiwan (Sun Ten Pharmaceutical Co., Ltd,
Taichung, Taiwan). The TCM medications were prescribed
for three times daily after meal. Each dosagecomprised 5g of
TCM powder.
2.3. Measurements. A structured four-part questionnaire
was used to collect demographic data, including age, gender
and disease history, such as hypertension, diabetes melli-
tus and hepatitis virus status. The second part collected
disease and treatment data, including diagnosis, cancer
stage, cancer status (newly diagnosed or recurrence), timing
of chemotherapy (before or after surgery) and site of
radiotherapy. The third part collected chemotherapeutic
drugs and chemotherapy course data. Chemotherapeutic
drugs which could cause damage to the liver cells of
recipients were classiﬁed as having potential hepatotoxicity.
Even chemotherapeutic drugs which were not classiﬁed
as having hepatotoxicity could induce poor liver function
among patients due to massive cell deaths resulting from
chemotherapy and increased metabolic load associated with
use of medicine. Therefore, we decided to include all courses
of chemotherapy and treat potential hepatotoxicity of the
chemotherapeutic drugs as a confounder in this study.
A chemotherapy course was regarded as complete when
it was not stopped or postponed, based on recorded
chemotherapyregimens.Thefourthpartcollectedliverfunc-
tion test data (AST and ALT) 1 week before chemotherapy,
during chemotherapy (the last week of chemotherapy), and
2 weeks after chemotherapy.
2.4. Data Analysis. The Statistical Package for the Social
Sciences(SPSS,version11.0forWindows,SPSSInc,Chicago,
IL) and Statistical Analysis System (SAS, version 8.2 SAS
Institute, Cary, NC) were used to perform the data anal-
yses. The characteristics of the study participants were
summarized as the mean ± standard deviation (SD) for
continuous variables and as proportions for categorical
variables. Student’s t-test and chi-square test were used, as
appropriate, to analyze group diﬀerences. The generalized
estimating equations (GEE) model was used to control the
eﬀect of study covariates and to analyze the independent
eﬀect of TCM therapy on liver function and completion of
chemotherapy [22]. The GEE approach has been proposed
as a non-parametric and appropriate method to conduct
the repeated measurement analysis. This study applied GEEEvidence-Based Complementary and Alternative Medicine 3
Table 1: Botanical names for the components of TCMs.
TCM medication
Xiao-Chai-Hu-Tang Huang-Lian-Jie-Du-Tang Yin-Chen-Wu-Ling-San
Buplerum chinense DC. The rhizome of Chinese goldthread Poria cocos tuckahoe
Pinellia ternate Scutellaria baicalensis Georgi Agaric umbellate pore fungus
Ginseng Phellodendri Cortex Largehead atractylodes Rh
Scutellaria baicalensis Georgi Gardeniae Fructus Cassia twigs, ramulus cinnamomi
Glycyrrhizae Radix Alismatis rhizoma
Ginger Artemisiae scopariae herba
Big jujube
to account for correlated data resulting from repeated
measurements across diﬀerent time points and multiple
observations(chemotherapy courses)ofthesame individual.
In all analyses, a 5% signiﬁcance level was used.
3.Results
3.1. Subject Demographics. Of the 89 patient records studied,
63% were women, 24% had hypertension, 16% had diabetes
mellitus, 8% carried hepatitis B virus and 3% carried hepati-
tis C virus. The age of the study participants raged from 28
to 88 years (mean 56.03, SD 12.75). Most of the patients had
gastrointestinal cancer (40%) and breast cancer (30%). The
cancer stages were stage IV (39%), stage III (36%), stage II
(18%) and stage I (7%). The majority of patients were newly
diagnosed with cancer (83%) (Table 2). Characteristics of
the courses of chemotherapy were compared by the case-
controlstatus(Table 3).There were nosigniﬁcant diﬀerences
between the case and control groups except for the cancer
diagnosis and cancer stage. More controls had a diagnosis
of breast cancer (45.2% versus 14.8%), while more cases
had a cancer stage of III and IV (83.8% versus 61.9%).
Chemotherapeutic drugs used in this study are listed in the
end note to Table 3.A b o u t9 7 %o fa l lc h e m o t h e r a p yc o u r s e s
used chemotherapeutic drugs with potential hepatotoxicity.
There were no signiﬁcant diﬀerences between the case and
controlgroupsintermsoftheuseofchemotherapeuticdrugs
with potential hepatotoxicity.
3.2. AST Levels. Among the 184 chemotherapy courses
(cases 42, controls 142), the mean AST did not diﬀer signiﬁ-
cantlybetweenthecaseandcontrolgroups1weekbeforeand
2 weeks after chemotherapy. However, the case group had
signiﬁcantly lower mean AST values during chemotherapy
(24.12 versus 29.20, P = .01; Table 4). Median AST values
c h a n g e dl i t t l ea n dd i dn o ts i g n i ﬁ c a n t l yd i ﬀer between the
case and control groups. Median AST values were 23Ul−1
for the cases at the three time points; while they were 23,
24 and 24Ul−1 for the controls 1 week before, during and
2 weeks after chemotherapy, respectively. The GEE results
showed that the case group had signiﬁcantly decreased AST
valuesduring chemotherapy rela t i v et ob e f o r ec h e m o t h e ra p y
than did the control group (β = −6.90, P = .01). There was
no signiﬁcant diﬀerence in AST after chemotherapy relative
to before chemotherapy between the case and control groups
Table 2: Characteristics of the study participants (N = 89).
n Percentage (%)
Age (years)
28–40 8 9.0
41–50 26 29.2
51–60 23 25.8
61–70 20 22.5
71–80 10 12.4
80–88 2 1.1
Sex
Male 33 37.1
Female 56 62.9
Cancer diagnosis
Breast cancer 27 30.3
Gastrointestinal cancer 36 40.4
Lung cancer 7 7.9
Lip, oral cavity, pharynx and
throat cancer 55 . 6
Genital and urological cancer 4 4.5
Lymph and blood system
cancer 77 . 9
Bone and connective tissue
cancer 22 . 2
Cancer stages
I6 6 . 7
II 16 18.0
III 32 36.0
IV 35 39.3
Cancer status
Newly diagnosed 74 83.1
Relapse 15 16.9
Hepatitis virus carrier
B7 7 . 9
C3 3 . 4
(β = −3.45, P = .30). The main eﬀect of time was signiﬁcant
in that during chemotherapy the participants had higher
mean AST values than before chemotherapy (β = 4.42, P <
.001); AST values before chemotherapy did not diﬀer from
those after chemotherapy (β = 1.78, P = .11). The main4 Evidence-Based Complementary and Alternative Medicine
Table 3: Characteristics by the case-control status (N = 184).
Case (n = 42) Control (n = 142) t/χ2 P
Age Mean = 58.43; SD = 12.28 Mean = 55.17; SD = 10.12 1.57 .12
Sex 2.28 .09
Male 14 (33.3%) 66 (46.5%)
Female 28 (66.7%) 76 (53.5%)
Cancer diagnosis 43.47 <.0001
Breast cancer 21 (14.8%) 19 (45.2%)
Gastrointestinal cancer 88 (62.0%) 8 (19.0%)
Lung cancer 15 (10.6%) 2 (4.8%)
Lip, oral cavity, pharynx and throat cancer 2 (1.4%) 4 (9.5%)
Genital and urological cancer 7 (4.9%) 3 (7.1%)
Lymph and blood system cancer 9 (6.3%) 3 (7.1%)
Bone and connective tissue cancer 0 (0.0%) 1 (2.4%)
Others 0 (0.0%) 2 (4.8%)
Cancer stages 19.15 <.001
I 2 (1.4%) 7 (16.7%)
II 21 (14.8%) 9 (21.4%)
III 51 (35.9%) 14 (33.3%)
IV 68 (47.9%) 12 (28.6%)
Site of radiotherapy 5.11 .08
No 58 (40.8%) 23 (54.8%)
Abdomen 45 (31.7%) 6 (14.3%)
Non-abdomen 39 (27.5%) 13 (31.0%)
Hepatotoxicity of the chemotherapeutic drugs 0.13 .72
Yes 41 (97.6%) 137 (96.5%)
No 1 (2.4%) 5 (3.5%)
t and χ2 are respective statistical values from Student’s; t-test and chi-squared test; the P-value is the probability assuming that null hypothesis is
true (two-tailed test); the signiﬁcance level was set to P < .05. The chemotherapeutic drugs used in this study were Ara-C, bleomycin, carboplatin,
cisplatin, cyclophosphamide, dacarbazine, doxorubicin, etoposide, ﬂuorouracil, formoxol, gemcitabine, ifosfamide, mitoxantrone, methotrexate, mitomycin
C,oxaliplatin,taxolandtaxotere(withpotentialhepatotoxicity);arimidex,CPT-11,faslodex,herceptin,navelbine,tamoxifen,UFUR andvinblastine(without
hepatotoxicity).
eﬀect of case-control status was not signiﬁcant (β = 2.48,
P = .39). After adjusting for study covariates including age,
gender, cancer stage, site of radiotherapy, cancer diagnosis
and potential hepatotoxicity of the chemotherapeutic drugs,
the study results remain quite similar that the signiﬁcantly
lower AST for the case group compared to the control group
during chemotherapy was sustained (β = −6.9,P = .01).AST
valuesdid not diﬀer2 weeks after chemotherapy between the
case and control groups (β = −3.48, P = .30). The signiﬁcant
eﬀect of time (higher AST values during chemotherapy than
before chemotherapy) was sustained (β = 4.43, P < .001)
(Table 5).
3.3. ALT Levels. Mean ALT did not diﬀer signiﬁcantly
between the case and control groups at all three time points
(1 week before, during and 2 weeks after chemotherapy).
Nonetheless, the case group had lower mean ALT values
during thechemotherapy with borderline signiﬁcance (22.60
versus 26.33, P = .08; Table 4). Median ALT values did not
signiﬁcantly diﬀer between the case and control groups.
Median ALT values were 20.5, 22.5 and 21.5Ul−1 for the
case group, and 18, 19 and 19Ul−1 for the controls 1 week
before, during and 2 weeks after chemotherapy, respectively.
The GEE results showed that the case group had signiﬁcantly
decreased mean ALT values during chemotherapy relative
to before chemotherapy than controls (β = −5.99,P= .03).
There was no signiﬁcant diﬀerence in ALT after chemother-
apy relative to before chemotherapy between the case and
control groups (β = −0.75, P = .83). The main eﬀect of time
was signiﬁcant in that during chemotherapy the participants
had higher mean ALT values than before chemotherapy (β =
3.77, P = .01); ALT values before chemotherapy did not
diﬀerfrom those after chemotherapy (β = 1.33,P = .38).The
main eﬀect of case-control status was not signiﬁcant (β =
0.44, P = .84). After adjusting for study covariates including
age, sex, cancer stage, site of radiotherapy, cancer diagnosis,
and potential hepatotoxicity of the chemotherapeutic drugs,
the study results also remain similar that the signiﬁcantly
lower ALT for cases than controls during chemotherapy
was sustained (β = −5.95, P = .03). ALT values did not
diﬀer 2 weeks after chemotherapy between the case and
control groups (β = −0.75, P = .83). The signiﬁcant eﬀect of
time (higher ALT values during chemotherapy than before
chemotherapy) was sustained (β = 3.77, P = .01) (Table 6).Evidence-Based Complementary and Alternative Medicine 5
Table 4: Mean AST and ALT values by case-control status.
Case (n = 42) Control (n = 142) tP
Mean SD Mean SD
AST before chemotherapy 26.55 16.04 24.76 10.09 −0.82 .41
AST during chemotherapy 24.12 5.37 29.20 20.07 2.61 .01
AST after chemotherapy 25.49 7.73 26.67 14.32 0.50 .61
ALT before chemotherapy 24.17 15.34 22.70 15.65 −0.53 .59
ALT during chemotherapy 22.60 6.97 26.33 20.90 1.76 .08
ALT after chemotherapy 24.74 15.88 24.35 17.08 −0.13 .89
t isthe statisticalvaluefrom Student’s;t-test;the P-value is theprobabilityassumingthatthe null hypothesis istrue (two-tailedtest);the signiﬁcancelevel was
set to P < .05.
Table 5: Crude and net eﬀect of TCM use on AST.
Estimate 95% CI Z P
Crude eﬀect
TCM cases 2.48 −3.21 8.19 0.85 .39
During chemotherapy 4.42 2.01 6.82 3.60 <.001
After chemotherapy 1.78 −0.46 4.04 1.56 .11
Case × During −6.90 −12.30 −1.50 −2.51 .01
Case × After −3.45 −10.08 3.17 −1.02 .30
Net eﬀect
TCM cases 3.61 −2.47 9.70 1.16 .24
During chemotherapy 4.43 2.01 6.85 3.59 .0003
After chemotherapy 1.81 −0.44 4.05 1.60 .11
Case × During −6.9 −12.30 −1.50 −2.51 .01
Case × After −3.48 −10.08 3.11 −1.03 .30
The reference groups were controls for case–control status and before chemotherapyfor time.
Crude eﬀectwasunadjustedresults.Net eﬀect wasresultsadjustedforage, sex,cancer stage,siteofradiotherapy, cancerdiagnosis and potential hepatotoxicity
of the chemotherapeuticdrugs.
Z is the statisticalvalue from GEE; the P value is the probability assumingthat the null hypothesis is true (two-tailed test);the signiﬁcance level was set to P <
.05; “×” indicates an interaction.
3.4. Chemotherapy Completion. The chemotherapy comple-
tion rate was 76% (32/42) for the case group and 59%
(84/142) for the control group (P = .04). The GEE results
showed that the case group tended to have higher odds
of completing chemotherapy, but the results were not
statistically signiﬁcant [odds ratio (OR) = 1.64, P = .16].
Furthermore, after adjusting for age, sex, cancer stage, site of
radiotherapy, cancer diagnosis, and potential hepatotoxicity
of the chemotherapeutic drugs, there were no signiﬁcant
diﬀerences between the case and control groups for odds of
completingonecourseofchemotherapy(OR=1.59,P =.21).
4.Discussion
We showed that TCM for patients with cancer receiving
chemotherapy protected liver function during chemother-
apy, as evidenced by lower blood AST and ALT levels,
but the eﬀect disappeared 2 weeks after chemotherapy.
After adjustment for demographics and disease related
factors, TCM lowered AST by 6.9Ul−1 (22.9%) and ALT
by 5.95Ul−1 (19.7%) during chemotherapy. At 2 weeks
after chemotherapy, the AST and ALT values returned to
levels similar to the value 1 week before chemotherapy
for the case group. For the control group, AST and ALT
values signiﬁcantly increased during chemotherapy then
decreased to the level only slightly higher than the values
before chemotherapy at 2 weeks after chemotherapy. A
previous study showed that AST rose during chemotherapy
then declined 3 days after chemotherapy [23]. The pattern
was consistent with the trend among the controls in this
study. The diﬀerent pattern of AST- and ALT-value changes
between the case and control groups in this study suggests
eﬃcacy of TCM for liver protection during chemotherapy.
T h ep r o p o s e ds c h e m ef o rt h ee ﬀect of TCM on liver
protection is presented in Figure 1.D u r i n gc h e m o t h e r a p y ,
the drugs stimulate liver and hepatic cells to detoxify and
metabolize the chemotherapeutic drugs and this process can
cause liver damage such as hepatitis and hepatic necrosis
[24, 25]. When the liver is damaged, hepatic cells secrete
AST and ALT, which can be detected in the serum. Thus,
serum AST and ALT levels were used to assess the extent
of damage to hepatic cells. Research shows that TCM
decreased liver damage in the case of acute hepatitis through
decreasing degeneration of hepatic cells and delaying or
preventing liver ﬁbrosis [26, 27]. In addition, TCM has
antidotal properties that reduce superoxide anion activity
[28]. In other words, TCM could prevent liver injury6 Evidence-Based Complementary and Alternative Medicine
Table 6: Crude and net eﬀect of TCM use on ALT.
Estimate 95% CI Z P
Crude eﬀect
TCM cases 0.44 −3.99 4.88 0.20 0.84
During chemotherapy 3.77 0.68 6.86 2.39 0.01
After chemotherapy 1.33 −1.68 4.34 0.87 0.38
Case × During −5.99 −11.50 −0.47 −2.13 0.03
Case × After −0.75 −7.81 6.29 −0.21 0.83
Net eﬀect
TCM cases −0.33 −5.47 4.81 −0.13 0.89
During chemotherapy 3.77 0.68 6.87 2.39 0.01
After chemotherapy 1.33 −1.68 4.34 0.87 0.38
Case × During −5.95 −11.47 −0.44 −2.12 0.03
Case × After −0.75 −7.79 −6.27 −0.21 0.83
The reference groups were controls for case-control status and before chemotherapyfor time.
Crude eﬀectwas unadjustedresults.Net eﬀectwasresultsadjustedforage,sex,cancerstage,siteofradiotherapy,cancerdiagnosis,andpotentialhepatotoxicity
of the chemotherapeuticdrugs.
Z is the statisticalvalue from the GEE; the P value is the probability assumingthat the null hypothesis is true (two-tailed test);the signiﬁcance level was set to
P < .05; “ ×” indicates an interaction.
during chemotherapy through its antioxidant function and
decreasing degeneration of liver cells or ﬁbrosis. The other
plausibleexplanationsofthebeneﬁcialeﬀectofTCMonliver
function are hyperplasia of hepatic cells and formation of
interferon.TCMpreparationssuchastherhizomeofChinese
goldthread and umbellate pore fungus induce formation of
interferon; the rhizome of Chinese goldthread also induces
hyperplasia of hepatic cells [29, 30]. Hyperplasia of hepatic
cells alleviates metabolic load and interferon treats hepatitis.
Therefore, when patients with cancer receive chemotherapy,
TCMpreparationscouldstimulatethelivertoproliferateand
secrete interferon, activating liver self-defenses. At 2 weeks
after chemotherapy, when no chemotherapeutic drugs were
present to stimulate the hepatic cells, the eﬀect of the TCM
preparation disappeared. Determination of the mechanisms
linking TCM preparations to improved liver function during
chemotherapy were outside the scope of this study. Further
studiesare needed to examine the underlying mechanisms of
TCM action.
W h i l ew ef o u n dt h a tt h eT C Mp r e p a r a t i o n sh a dn o
signiﬁcant eﬀect on completion of chemotherapy among
patients with cancer, the patients who had TCM in con-
junction with chemotherapy tended toward a higher rate of
chemotherapy completion than those who had chemother-
apy alone. There were many possible reasons why patients
did not complete chemotherapy besides poor liver function
and physical health. Reasons for cancellation and delay of
chemotherapy were not available for analysis in the current
study. More accurate measurement of this variable may yield
diﬀerent results. Further study is needed to examine whether
TCM could increase chemotherapy completion rates.
There are a number of TCM preparations that are
used to protect or improve liver function based on TCM
theory. According to TCM theory, TCM preparations should
be adjusted by adding or eliminating ingredients in order
to agree with an individual’s constitution. Therefore, the
contents of TCM preparations vary based on patients’
conditions and TCM doctors’ recommendations. The TCM
preparations used in this study were prescribed by licensed
TCM doctors. Three multiple-herb preparations were used
as the base, including Huang-Lian-Jie-Du-Tang, Yin-Chen-
Wu-ling-san and Xiao-Chai-Hu-Tang. Other studies of TCM
preparations showed improved liver function [29, 31–33].
The TCM preparations used in those studies had some
overlap of herb components with those used in our current
study. Nonetheless, there were still diﬀerences in herb
components, thus, the comparability of results is limited.
4.1. Limitations. This case-control study used course of
chemotherapy rather than individual patient as unit of
analysis, and GEE was applied to account for the correlated
data. This approach could enhance the comparability of
the case and control courses and increase data eﬃciency,
since diﬀerent courses of the same individual could serve
either as cases or controls depending on whether TCM was
used. Despite these, the allotment of case and control status
was based on patient’s decisions to seek TCM treatment
with or without an oncologist’s referral. Therefore, there
may be a concern for potential selection bias, but the
use of objective rather than subjective indicators as the
outcome variables and the use of statistical methods to
adjust for confounders may mitigate this concern. This
study included patients with diﬀerent cancer diagnoses and
on diﬀerent chemotherapeutic drugs. Due to the small
number of patients in this study, subgroup analysis could
not be performed. Nonetheless, the signiﬁcant eﬀects of
l o w e r e dA S Ta n dA L Tw e r es u s t a i n e dg i v e nt h a tt h eG E E
approach was used to account for correlated observations
and adjustment for potential confounders in the study. A
future study with more-homogeneous samples and a larger
sample size is needed. Potential interactions between TCMs
and chemotherapeutic drugs should be examined in future
studies. There is a lackofinformation on otherindicatorsfor
liver function such as GGT, bilirubin and ALD in this study.Evidence-Based Complementary and Alternative Medicine 7
Hepatic cells metabolize and detoxify chemotherapeutic drugs
Chemotherapy
TCM
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Figure 1: Proposed scheme for the eﬀect of TCMs on liver protection among cancer patients receiving chemotherapy.
This study only examined a limited spectrum of patient
outcomes; in addition to a more-complete liver proﬁle,
information about the treatment eﬃcacy such as tumor
reduction, relapse and blood proﬁle should be considered in
future studies.
5.Conclusion
Integrative care for cancer patients using modern medicine
and TCM is an emerging trend. We demonstrated that
use of TCM preparations improved liver function during
chemotherapy among our patients with cancer receiving
chemotherapy. Randomized controlled trails are warranted
in order to conﬁrm the eﬀectiveness of various TCM
preparations for protection of liver function among cancer
patients receiving chemotherapy.
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